Yunoki S, Tanaka N, Hizuta A, Orita K
First Department of Surgery, Okayama University Medical School, Japan.
Int J Immunopharmacol. 1994 Feb;16(2):123-30. doi: 10.1016/0192-0561(94)90068-x.
We have studied the effects of oral administration of a biological response modifier (BRM), PSK, on hepatic lymphocytes. Many PSK positive cells were observed in the liver by anti-PSK antibody staining. Flow cytometric analysis revealed an increase in the number of OX8 (CD8) positive cells in the non-parenchymal nonadherent liver cells (NPNALCs) which were isolated from the liver enzymatically digested by perfusion with collagenase. NPNALCs were fractionated by discontinuous density gradient centrifugation, and the number and cytotoxic activity of these cells were examined in each fraction. Although the yield of lymphocytes in each fraction was not significantly increased by the oral administration of PSK, the natural killer (NK) activity was markedly enhanced in low density fractions. The present findings suggest that oral administration of PSK is effective for prevention of liver metastasis through the augmentation of organ-associated NK activity.
我们研究了口服生物反应调节剂(BRM)PSK对肝淋巴细胞的影响。通过抗PSK抗体染色在肝脏中观察到许多PSK阳性细胞。流式细胞术分析显示,从用胶原酶灌注酶解的肝脏中分离出的非实质非贴壁肝细胞(NPNALCs)中,OX8(CD8)阳性细胞数量增加。通过不连续密度梯度离心对NPNALCs进行分级分离,并检测各分级中这些细胞的数量和细胞毒性活性。虽然口服PSK后各分级中淋巴细胞的产量没有显著增加,但低密度分级中的自然杀伤(NK)活性明显增强。目前的研究结果表明,口服PSK通过增强器官相关NK活性对预防肝转移有效。